ClinicalTrials.gg
CompletedNCT00137462Updated Nov 16, 2007

Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.

A Phase 3 interventional study of torcetrapib/atorvastatin and atorvastatin in Hyperlipidemia, sponsored by Pfizer. Completed at 59 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2007-11-16.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
900
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 37 studies testing atorvastatin in Hyperlipidemias — none open to participants now, none under way, none of them phase 3. Atorvastatin · Hyperlipidemias.

Enrollment
4th of 37
900 · median 99
Started
2004
with 2 others
Phase 3
10 of 37
none open now
Registered
6th of 37
by date
Lead sponsor
5 of 37
Pfizer

Among the 37 studies testing atorvastatin in Hyperlipidemias, this one is the 4th largest by enrollment, is one of 3 that started in 2004, is one of 10 in phase 3, and was the 6th registered.

Hyperlipidemias

862 studies on the registry are indexed under Hyperlipidemias; 108 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

None of the 37 studies testing atorvastatin in Hyperlipidemias is open now. The open studies under Hyperlipidemias, anywhere →

About atorvastatin

Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 66 Hyperlipidemias studies recruiting now, 26 (39%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 37 studies testing atorvastatin in Hyperlipidemias as a file.
02

Study summary

The Torcetrapib project was terminated on December 2, 2006 due to safety findings.

To look at various lipids in the blood of people with Fredrickson Type IIa and Type IIb mixed dyslipidemias

Read the detailed description

For additional information please call: 1-800-718-1021

03

Conditions studied

  • Hyperlipidemia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Statin eligible per NCEP ATP-III guidelines
  • At least 18 years of age

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or lactating, or planning to become pregnant
  • Intolerance to statin therapy
  • Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors
  • Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluation of response, or render unlikely that the subject would complete the study
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
900 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Change in lipid parameters (HDL, LDL) at various timepoints over 12 months.

Secondary outcomes

  1. Changes in levels of lipids and other biomarkers.

07

Study locations

59 sites
  • Pfizer Investigational Site
    Huntsville, Alabama 35802, United States
  • Pfizer Investigational Site
    Union Grove, Alabama 35175, United States
  • Pfizer Investigational Site
    Fresno, California 93720, United States
  • Pfizer Investigational Site
    Los Angeles, California 90057, United States
  • Pfizer Investigational Site
    Orange, California 92868, United States
  • Pfizer Investigational Site
    San Diego, California 92128, United States
  • Pfizer Investigational Site
    Denver, Colorado 80220, United States
  • Pfizer Investigational Site
    Denver, Colorado 80262, United States
  • Pfizer Investigational Site
    Golden, Colorado 80401, United States
  • Pfizer Investigational Site
    Bridgeport, Connecticut 06610, United States
  • Pfizer Investigational Site
    Fairfield, Connecticut 06824, United States
  • Pfizer Investigational Site
    Trumbull, Connecticut 06611, United States
  • Pfizer Investigational Site
    Waterbury, Connecticut 06708, United States
  • Pfizer Investigational Site
    Washington, District of Columbia 20037, United States
  • Pfizer Investigational Site
    Boynton Beach, Florida 33437, United States
  • Pfizer Investigational Site
    Fort Lauderdale, Florida 33308, United States
  • Pfizer Investigational Site
    Gainesville, Florida 32605, United States
  • Pfizer Investigational Site
    Gainesville, Florida 32610, United States
  • Pfizer Investigational Site
    Gainsville, Florida 32610, United States
  • Pfizer Investigational Site
    Sebastian, Florida 32958, United States
  • Pfizer Investigational Site
    Vero Beach, Florida 32960, United States
  • Pfizer Investigational Site
    Rockford, Illinois 61108, United States
  • Pfizer Investigational Site
    Springfield, Illinois 62704, United States
  • Pfizer Investigational Site
    Olathe, Kansas 66061, United States
  • Pfizer Investigational Site
    Overland Park, Kansas 66210, United States
  • Pfizer Investigational Site
    Madisonville, Kentucky 42431, United States
  • Pfizer Investigational Site
    Burlington, Massachusetts 01805, United States
  • Pfizer Investigational Site
    Grand Rapids, Michigan 49525, United States
  • Pfizer Investigational Site
    Troy, Michigan 48098, United States
  • Pfizer Investigational Site
    Albuquerque, New Mexico 87102, United States
  • Pfizer Investigational Site
    Albuquerque, New Mexico 87106, United States
  • Pfizer Investigational Site
    Orchard Park, New York 14127, United States
  • Pfizer Investigational Site
    Syracuse, New York 13202, United States
  • Pfizer Investigational Site
    Syracuse, New York 13210, United States
  • Pfizer Investigational Site
    Williamsville, New York 14221, United States
  • Pfizer Investigational Site
    Charlotte, North Carolina 28262, United States
  • Pfizer Investigational Site
    Cleveland, Ohio 44126, United States
  • Pfizer Investigational Site
    Columbus, Ohio 43214, United States
  • Pfizer Investigational Site
    Keizer, Oregon 97303, United States
  • Pfizer Investigational Site
    Salem, Oregon 97302, United States
  • Pfizer Investigational Site
    Doylestown, Pennsylvania 18901, United States
  • Pfizer Investigational Site
    Charleston, South Carolina 29425, United States
  • Pfizer Investigational Site
    Mt. Pleasant, South Carolina 29464, United States
  • Pfizer Investigational Site
    Mt. Pleasant, South Carolina 83464, United States
  • Pfizer Investigational Site
    Kingsport, Tennessee 37660, United States
  • Pfizer Investigational Site
    Morristown, Tennessee 37813, United States
  • Pfizer Investigational Site
    Dallas, Texas 75230, United States
  • Pfizer Investigational Site
    McKinney, Texas 75069, United States
  • Pfizer Investigational Site
    Edmonton, Alberta T6G 2B7, Canada
  • Pfizer Investigational Site
    Coquitlam, British Columbia V3K 3P4, Canada
  • Pfizer Investigational Site
    London, Ontario N6C 5J1, Canada
  • Pfizer Investigational Site
    London, Ontario N6G 2M3, Canada
  • Pfizer Investigational Site
    Ottawa, Ontario K1H 8K7, Canada
  • Pfizer Investigational Site
    Sarnia, Ontario N7T 4X3, Canada
  • Pfizer Investigational Site
    Toronto, Ontario M9W 4L6, Canada
  • Pfizer Investigational Site
    Charlottetown, Prince Edward Island C1A 1L2, Canada
  • Pfizer Investigational Site
    Mirabel, Quebec J7J 2K8, Canada
  • Pfizer Investigational Site
    Pointe-Claire, Quebec H9R 4S3, Canada
  • Pfizer Investigational Site
    St. Georges de Beauce, Quebec G5Y 4W1, Canada
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2004 and a completion of Sep 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2005
First posted
Aug 29, 2005
Start
Nov 2004
Completion
Sep 2006
Last update
Nov 16, 2007
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Nov 16, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00137462
Lead sponsor
Pfizer
First posted
Aug 29, 2005
Start date
Nov 2004
Completion
Sep 2006
Last update
Nov 16, 2007

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Torcetrapib · Atorvastatin

Start the discussion